Product References — Pooled Human AB Serum Plasma Derived

Multiple Site Place-of-Care Manufactured Anti-CD19 CAR-T Cells Induce High Remission Rates in B-cell Malignancy Patients

Posted by Adam Awdish on

Multiple Site Place-of-Care Manufactured Anti-CD19 CAR-T Cells Induce High Remission Rates in B-cell Malignancy Patients

Pooled Human AB Serum Plasma Derived from Innovative Research was used in the following study:   Multiple Site Place-of-Care Manufactured Anti-CD19 CAR-T Cells Induce High Remission Rates in B-cell Malignancy Patients Michael Maschan, Paolo F. Caimi, Jane Reese-Koc, Gabriela Pacheco Sanchez, Ashish A. Sharma, Olga Molostova, Larisa Shelikhova, Dmitriy Pershin, Alexey Stepanov, Yakov Muzalevskii, Vinicius G. Suzart, Folashade Otegbeye, David Wald, Ying Xiong, Darong Wu, Adam Knight, Ibe Oparaocha, Beatrix Ferencz, Andre Roy, Andrew Worden, Winfried Kruger, Michael Kadan, Dina Schneider, Rimas Orentas, Rafick-Pierre Sekaly, Marcos de Lima & Boro Dropulić Nature Communications December 10, 2021 Pediatric B-acute lymphoblastic leukemia...

Read more →

Expression of Placenta-Specific 1 and its Potential for Eliciting Anti-Tumor Helper T-cell Responses in Head and Neck Squamous Cell Carcinoma

Posted by Adam Awdish on

Expression of Placenta-Specific 1 and its Potential for Eliciting Anti-Tumor Helper T-cell Responses in Head and Neck Squamous Cell Carcinoma

Pooled Human AB Serum Off The Clot from Innovative Research was used in the following study:   Expression of Placenta-Specific 1 and its Potential for Eliciting Anti-Tumor Helper T-cell Responses in Head and Neck Squamous Cell Carcinoma Ryusuke Hayashi, Toshihiro Nagato, Takumi Kumai, Kenzo Ohara, Mizuho Ohara, Takayuki Ohkuri, Yui Hirata-Nozaki, Shohei Harabuchi, Akemi Kosaka, Marino Nagata, Yuki Yajima, Syunsuke Yasuda, Kensuke Oikawa, Michihisa Kono, Kan Kishibe, Miki Takahara, Akihiro Katada, Tatsuya Hayashi, Esteban Celis, Yasuaki Harabuchi, and Hiroya Kobayashi OncoImmunology December 29, 2020 Various cancers of the head and neck are frequent around the globe, with the most common...

Read more →

HLA DRB1*15:01-DQB1*06:02-Restricted Human CD4+ T-Cells are Selectively Activated with Amoxicillin-Peptide Adducts

Posted by Adam Awdish on

HLA DRB1*15:01-DQB1*06:02-Restricted Human CD4+ T-Cells are Selectively Activated with Amoxicillin-Peptide Adducts

Pooled Human AB Serum Plasma Derived from Innovative Research was used in the following study:   HLA DRB1*15:01-DQB1*06:02-Restricted Human CD4+ T-Cells are Selectively Activated with Amoxicillin-Peptide Adducts Arun Tailor, Xiaoli Meng, Kareena Adair, John Farrell, James C Waddington, Ann Daly, Munir Pirmohamed, Gordon Dear, B Kevin Park, Dean J Naisbitt Toxicological Sciences August 10, 2020 Idiosyncratic drug-induced liver injury (DILI) is a major health concern often associated with a high patient death rate. Amoxicillin-clavulanate is the most common cause of DILI, and the detection of drug-specific CD4+ T-cells in patients with DILI suggests it originates somewhere in the immune system....

Read more →

Effects of Different Separation Methods on the Physical and Functional Properties of Extracellular Vesicles

Posted by Adam Awdish on

Effects of Different Separation Methods on the Physical and Functional Properties of Extracellular Vesicles

Pooled Human AB Serum Off The Clot from Innovative Research was used in the following study:   Effects of Different Separation Methods on the Physical and Functional Properties of Extracellular Vesicles Hyungtaek Jeon, Su-Kyung Kang, Myung-Shin Lee PLoS ONE July 7, 2020 Extracellular vesicles (EVs) are nano-sized membrane vesicles (20–500 nm) of endocytic origin that are secreted by most cells under normal physiological conditions, as well as by cells undergoing pathological processes. EVs contain a variety of molecules such as proteins, nucleic acids, and lipids, which are affected by environmental factors and health conditions, making them potential biomarkers for diseases...

Read more →

CD19-Targeted CAR Regulatory T Cells Suppress B Cell Pathology without GvHD

Posted by Adam Awdish on

CD19-Targeted CAR Regulatory T Cells Suppress B Cell Pathology without GvHD

Pooled Human AB Serum Plasma Derived from Innovative Research was used in the following study:   CD19-Targeted CAR Regulatory T Cells Suppress B Cell Pathology without GvHD Yuki Imura, Makoto Ando, Taisuke Kondo, Minako Ito, and Akihiko Yoshimura JCI Insight July 23, 2020 Tregs suppress excess immunity responses against a variety of antigens, including self-antigens, bacteria–derived antigens, and environmental allergens. Thus, Tregs have been shown to play important roles in suppressing the development of allergies. In humans, some clinical trials of transfer of ex vivo expanded polyclonal Tregs have been performed to suppress graft-versus-host disease (GvHD) after allogeneic hematopoietic stem...

Read more →


×